NDAOPHTHALMICSOLUTION/DROPS
Approved
Apr 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
4/8 — Partial
VIGAMOX (moxifloxacin hydrochloride) by Teva is 12. First approved in 2003.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIGAMOX is a fluoroquinolone antibiotic (moxifloxacin hydrochloride) delivered as an ophthalmic solution for topical eye treatment. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, disrupting bacterial DNA replication. The drug is indicated for bacterial eye infections and demonstrates excellent ocular penetration with approximately 90% oral bioavailability and a 12-hour half-life.
$0.167MPart D
LOE ApproachingAs LOE approaches, commercial teams are likely focused on maximizing existing volume and managing market transitions rather than expansion; expect rightsizing of sales and marketing resources.
Mechanism of Action
12.1 Mechanism of Action Moxifloxacin hydrochloride is a member of the fluoroquinolone class of antibacterial agents [see ] . 12.2 Pharmacodynamics Photosensitivity Potential A study of the skin response to ultraviolet (UVA and UVB) and visible radiation conducted in 32 healthy volunteers (8 per…
Worked on VIGAMOX at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.